Cantargia announces new pre-clinical results showing consistent positive effects of the antibody CAN04 when combined with platinum-based chemotherapies

Booking.com

Cantargia AB today announces new pre-clinical results from the antibody CAN04 (nidanilimab) in combination with platinum-based chemotherapies. Cantargia has previously reported synergistic antitumor effects between and the platinum compound cisplatin and CAN04. The new preclinical results show synergistic antitumor effects in vivo using CAN04 also in combination with carboplatin or oxaliplatin as well as CAN04 combined with the cisplatin and gemcitabine doublet. In all these settings, CAN04 also counteracted the chemotherapy-induced toxicity. CAN04 is currently combined with cisplatin and

Source: Cantargia announces new pre-clinical results showing consistent positive effects of the antibody CAN04 when combined with platinum-based chemotherapies

Booking.com
Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.